ClinicalTrials.gg
TerminatedNCT05984784Updated Nov 6, 2025Results posted

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

A Phase 1/2 interventional study of Placebo and IMG-007 in Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis and AD, sponsored by Inmagene LLC. Terminated at 12 sites in 2 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-11-06.

Sponsored by Inmagene LLC · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Cohort 1 was completed. Cohort 2 was cancelled because data from Cohort 1 provided sufficient information for further development decision. No safety concerns were noted.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
491st of 544
13 · median 96
Started
2023
with 49 others
Phase 1/2
15 of 639
none open now
Registered
517th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 491st largest by enrollment of the 544 interventional ones that give a count, is one of 50 that started in 2023, is one of 15 in phase 1/2, and was the 517th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety of IMG-007 in adults with moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and efficacy of IMG-007 in AD patients.

Read the detailed description

This is a phase 1b/2a study to assess the safety, tolerability, PK, efficacy, and PD of multiple doses of IMG-007 in participants with AD. The study will consist of two cohorts with three periods: a screening period of up to 5 weeks, a 12-week treatment period, and a 12-week follow-up period. Cohort 1 is open-label, with approximately 15 participants to receive three IV infusions of IMG-007 Dose 1 over 4 weeks. Cohort 2 is randomized, double-blind and placebo-controlled, with approximately 40 participants to be randomized in a 3:1 ratio to receive three IV infusions of IMG-007 Dose 2 or matching placebo over 4 weeks.

03

Conditions studied

  • Atopic Dermatitis
  • Moderate-to-severe Atopic Dermatitis
  • AD

Keywords

  • IMG-007
  • Atopic Dermatitis
  • Dermatitis, Atopic
  • Dermatitis
  • Eczema
  • Skin Diseases
  • Immune System Diseases
  • Dermatologic Agents
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female aged ≥ 18 and \< 75 years.
  • Moderate-to-severe AD.
  • Documented history of inadequate response or lack of tolerability to a stable regimen of one or more topical treatment before the Screening visit, or for whom topical treatments are otherwise inadvisable.
  • Female participants who are not pregnant or breastfeeding and meet at least one of the following conditions: not of or of childbearing potential and agrees to use a highly effective method of .

Key Exclusion Criteria:

  • Known , , or infection.
  • Evidence of active or latent tuberculosis (TB).
  • History of untreated or inadequately treated TB infection.
  • Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals at the Screening visit.
  • Active unstable pruritic skin conditions in addition to AD that would interfere with the assessment of AD based on the investigator's clinical judgement.
  • Other conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Cohort 1 IMG-007 Dose 1

    IMG-007 Dose 1 will be administered intravenously 3 times over 4 weeks

    Drug: IMG-007

  • Experimental
    Cohort 2 IMG-007 Dose 2

    IMG-007 Dose 2 will be administered intravenously 3 times over 4 weeks

    Drug: IMG-007

  • Placebo comparator
    Placebo

    Placebo will be administered intravenously 3 times over 4 weeks

    Drug: Placebo

Interventions

  • DrugPlacebo

    Drug: Placebo Intravenous Infusion

  • Drug: IMG-007 Intravenous Infusion

06

What researchers measure

Primary outcomes

  1. Evaluation of Adverse Events in Participants

    To evaluate adverse events (AEs) emergent from multiple doses of IMG-007 in adult participants with atopic dermatitis (AD)

    Time frame: Adverse events were collected from baseline through the end of the study, a period of up to 24 weeks.

Secondary outcomes

  1. Pharmacokinetic Characterization

    To characterize the pharmacokinetic (PK) profile of multiple doses of IMG-007 in AD participants

    Time frame: Serum concentrations of IMG-007 were measured at Week 4 (pre-dose and post-dose), Week 12 (post-dose), and Week 24 (post-dose).

  2. Evaluation of Eczema Area and Severity Index (EASI)

    The Eczema Area and Severity Index (EASI) is a validated composite scoring system assessed by the investigator based on the body area involved in each of the four body regions (head and neck, upper limbs, lower limbs, and trunk) and the average severity of each of the four key signs of AD (erythema, edema/papulation, excoriation, and lichenification) based on a 4-point scale of 0 (none), 1 (mild), 2 (moderate), and 3 (severe). The total EASI score ranges from 0 (clear or no eczema) to 72 (maximum severity), with higher values indicating more severe and/or extensive disease.

    Time frame: Mean percent change from baseline in Eczema Area and Severity Index (EASI) at week 12.

07

Results

Posted Nov 6, 2025

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 IMG-007 Dose 1
Started13
Completed8
Not completed5

Outcome measures

PrimaryEvaluation of Adverse Events in Participants

To evaluate adverse events (AEs) emergent from multiple doses of IMG-007 in adult participants with atopic dermatitis (AD)

Time frame:
Adverse events were collected from baseline through the end of the study, a period of up to 24 weeks.
Reported as:
Number · participants
Evaluation of Adverse Events in Participants
participantsCohort 1 IMG-007 Dose 1
Participants with at least 1 TEAE9
SAE0
Investigational product-related TEAE0
TEAE that was an infusion-related reaction0
TEAE leading to 4-week dosing period discontinuation0
TEAE with outcome of death0
SecondaryPharmacokinetic Characterization

To characterize the pharmacokinetic (PK) profile of multiple doses of IMG-007 in AD participants

Time frame:
Serum concentrations of IMG-007 were measured at Week 4 (pre-dose and post-dose), Week 12 (post-dose), and Week 24 (post-dose).
Reported as:
Mean · ng/mL
Pharmacokinetic Characterization
ng/mLCohort 1 IMG-007 Dose 1
Week 4, Pre-dose47650.0 ± 16255.6
Week 4, Post-dose131400.0 ± 18379.3
Week 12, Post-dose16088.0 ± 12662.2
Week 24, Post-Dose1334.2 ± 1720.5
SecondaryEvaluation of Eczema Area and Severity Index (EASI)

The Eczema Area and Severity Index (EASI) is a validated composite scoring system assessed by the investigator based on the body area involved in each of the four body regions (head and neck, upper limbs, lower limbs, and trunk) and the average severity of each of the four key signs of AD (erythema, edema/papulation, excoriation, and lichenification) based on a 4-point scale of 0 (none), 1 (mild), 2 (moderate), and 3 (severe). The total EASI score ranges from 0 (clear or no eczema) to 72 (maximum severity), with higher values indicating more severe and/or extensive disease.

Time frame:
Mean percent change from baseline in Eczema Area and Severity Index (EASI) at week 12.
Reported as:
Least squares mean · percentage of change
Evaluation of Eczema Area and Severity Index (EASI)
percentage of changeCohort 1 IMG-007 Dose 1
Evaluation of Eczema Area and Severity Index (EASI)-68.5 ± 11.4

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 IMG-007 Dose 10/13 (0%)0/13 (0%)9/13 (69.2%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventCohort 1 IMG-007 Dose 1
Dermatitis atopicSkin and subcutaneous tissue disorders4/13
UrticariaSkin and subcutaneous tissue disorders2/13
HypertensionVascular disorders2/13
COVID-19Infections and infestations1/13
localized infectionInfections and infestations1/13
NasopharyngitisInfections and infestations1/13
ConstipationGastrointestinal disorders1/13
DyslipidaemiaMetabolism and nutrition disorders1/13
ArthralgiaMusculoskeletal and connective tissue disorders1/13
Neck painMusculoskeletal and connective tissue disorders1/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1 IMG-007 Dose 1
Mean49.8 ± 15.0
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 IMG-007 Dose 1
Female4
Male9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 IMG-007 Dose 1
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American7
White6
More than one race0
Unknown or Not Reported0
EASI score
EASI score(units on a scale)Cohort 1 IMG-007 Dose 1
Mean29.5 ± 13.7
08

Study locations

12 sites
  • Amicis Research Center
    Northridge, California 91324, United States
  • Amicis Research Center
    Valencia, California 91355, United States
  • Medical Research Center of Miami II Inc
    Miami, Florida 33134, United States
  • Optimal Research Sites
    Orange City, Florida 32763, United States
  • USF Carol and Frank Morsani Center for Advanced Healthcare
    Tampa, Florida 33612, United States
  • Revival Research Institute, LLC
    Troy, Michigan 48084, United States
  • Markowitz Medical, LLC
    New York, New York 10128, United States
  • Central Sooner Research
    Oklahoma City, Oklahoma 73170, United States
  • Paddington Testing Co, Inc
    Philadelphia, Pennsylvania 19103, United States
  • Brunswick Dermatology Center
    Fredericton, New Brunswick E3B 1G9, Canada
  • DermEffects
    London, Ontario N6H 5L5, Canada
  • Centre de Recherche Saint-Louis (Québec)
    Québec, G1W4R4, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Data to be disclosed for primary and secondary endpoints.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Apr 2024, 8 months.

Results were first posted in Nov 2025, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2023
First posted
Aug 9, 2023
StartActual
Aug 9, 2023
Primary completionActual
Apr 26, 2024
CompletionActual
Apr 26, 2024
Results first posted
Nov 6, 2025
Last update
Nov 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05984784
Lead sponsor
Inmagene LLC
Responsible party
Sponsor
First posted
Aug 9, 2023
Start date
Aug 9, 2023
Primary completion
Apr 26, 2024
Completion
Apr 26, 2024
Results posted
Nov 6, 2025
Last update
Nov 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IMG-007

Start the discussion